3.2. Beta cell function in newly diagnosed T2D on early short-term insulin treatment or on glimepiride added to metformin, over 12 months of follow-up
T2D
INS
ΔC-Pep in INS group increased after 3 and 12 months, compared to the pretreatment values. The INS group improved STM-derived relative C-Pep (ΔC-Pep%) by 3 months (p = 0.000) and preserved this by 12 months (p = 0.000). The postprandial C-Pep to glucose ratio (PCPG) was also increased in the INS group at 3 months (p = 0.000) and remained so by 12 months (p = 0.000) (In the OAD group, ΔC-Pep increased from its pretreatment value after 3 (p = 0.000) and 12 months (p = 0.001). The OAD group improved STM-derived relative C-Pep increase (ΔC-Pep%) at 3 months (p = 0.000), preserving this by 12 months (p = 0.000). The PCPG at 3 and 12 months in the OAD group was increased compared to pretreatment testing (p = 0.000) Our analysis of the pretreatment STM-derived C-Pep response in the whole group of newly diagnosed T2D patients revealed its strong correlation to BMI. Thus, we have further compared results from the two groups by introducing the BMI-adjusted STM-stimulated relative C-Pep increase (BMDCP). This marker was greater at 3 months in the INS compared to the OAD group (4.60 ± 0.59 vs. 3.21 ± 0.34 mThere was no correlation of average AIP with any of the parameters of C-Pep response to STM: ΔC-Pep, ΔC-Pep%, PCPG—neither for the whole investigated cohort, nor for either sex separately.